SecSonar.com

Xencor, Inc. (XNCR)

Xencor, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Xencor, Inc. (XNCR) is a Biotechnology company based in US with a market capitalization of $885.3M. Revenue grew 13.7% year-over-year and free cash flow was negative at -$138.3M. This page tracks XNCR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 250 employees · IPO Dec 3, 2013

Valuation

Valuation & price

$11.22 · as of May 17, 2026 · -38.1% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.39

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$18.14$12.57$7.00Jul 25Dec 25Jul 26Jul 7, 25$7.94Jul 9, 25$9.33Jul 11, 25$8.83Jul 15, 25$8.44Jul 17, 25$9.07Jul 21, 25$9.10Jul 23, 25$9.57Jul 25, 25$9.24Jul 29, 25$8.82Jul 31, 25$8.32Aug 4, 25$7.95Aug 6, 25$7.49Aug 11, 25$7.00Aug 13, 25$7.72Aug 15, 25$7.68Aug 19, 25$7.59Aug 21, 25$7.44Aug 25, 25$8.01Aug 27, 25$8.02Aug 29, 25$8.13Sep 3, 25$8.33Sep 5, 25$8.55Sep 9, 25$8.31Sep 11, 25$8.50Sep 16, 25$8.62Sep 18, 25$10.03Sep 22, 25$10.39Sep 24, 25$10.47Sep 26, 25$11.57Sep 30, 25$11.73Oct 2, 25$11.82Oct 6, 25$11.79Oct 8, 25$12.40Oct 10, 25$13.03Oct 14, 25$12.43Oct 16, 25$14.95Oct 21, 25$14.51Oct 23, 25$12.34Oct 27, 25$14.27Oct 29, 25$14.67Oct 31, 25$14.71Nov 4, 25$13.70Nov 6, 25$14.00Nov 10, 25$13.74Nov 12, 25$14.39Nov 14, 25$14.93Nov 18, 25$16.02Nov 20, 25$15.58Nov 25, 25$17.26Nov 28, 25$17.32Dec 2, 25$15.99Dec 4, 25$18.14Dec 8, 25$17.68Dec 10, 25$17.16Dec 12, 25$16.52Dec 16, 25$16.55Dec 18, 25$15.69Dec 22, 25$15.97Dec 24, 25$15.45Dec 29, 25$15.17Jan 2, 26$14.92Jan 6, 26$14.06Jan 8, 26$14.19Jan 12, 26$14.17Jan 14, 26$14.45Jan 16, 26$12.79Jan 21, 26$13.00Jan 23, 26$12.78Jan 27, 26$13.17Jan 29, 26$12.38Feb 2, 26$12.11Feb 4, 26$11.53Feb 9, 26$11.93Feb 11, 26$12.22Feb 13, 26$11.59Feb 18, 26$11.34Feb 20, 26$11.41Feb 24, 26$11.81Feb 26, 26$13.55Mar 2, 26$12.30Mar 4, 26$12.74Mar 6, 26$11.32Mar 10, 26$11.98Mar 12, 26$11.61Mar 17, 26$11.74Mar 19, 26$12.12Mar 23, 26$12.05Mar 25, 26$12.40Mar 27, 26$11.42Mar 31, 26$12.06Apr 2, 26$12.81Apr 7, 26$12.31Apr 9, 26$12.53Apr 13, 26$12.07Apr 15, 26$12.51Apr 17, 26$13.06Apr 22, 26$12.85Apr 24, 26$12.98Apr 28, 26$12.15Apr 30, 26$11.93May 4, 26$13.36May 6, 26$13.01May 8, 26$12.86May 12, 26$12.44May 14, 26$11.88May 18, 26$11.06May 20, 26$11.32May 22, 26$11.31May 28, 26$11.97Jun 1, 26$11.80Jun 3, 26$11.42Jun 5, 26$11.77Jun 9, 26$11.89Jun 11, 26$12.09Jun 15, 26$12.21Jun 17, 26$12.78Jun 22, 26$14.01Jun 24, 26$14.45Jun 26, 26$15.05Jul 2, 26$15.00
$7.0052-week range$18.14
Loading valuation history…

Fundamentals

Key fundamentals

$885.3M

Market cap

13.7%

Revenue growth (YoY)

91.6%

Gross margin

-$138.3M

Free cash flow (USD)

-$360M

Net debt

Net cash position

14.1%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$87.5MFY 2017$35.7MFY 2018$40.6MFY 2019$156.7MFY 2020$122.7MFY 2021$275.1MFY 2022$164.6MFY 2023$174.6MFY 2024$110.5MFY 2025$125.6M
$87.5M$125.6M

Free cash flow by year

2016 → 2025

FY 2016$91.6MFY 2017$-41.0MFY 2018$-88.9MFY 2019$53.3MFY 2020$-18.8MFY 2021$-32.8MFY 2022$-18.9MFY 2023$-96.4MFY 2024$-208.3MFY 2025$-138.3M
$91.6M-$138.3M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202591.6%
100.0%91.6%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

6

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $89K · 10b5-1 PlanFeigal Ellen · Director · $89.4KJun 22, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 18, 2026Filing
  • Insider sellInsider Sell $62K · 10b5-1 PlanMontgomery Alan Bruce · Director · $62.3KJun 17, 2026Filing
  • Insider sellInsider Sell $67K · 10b5-1 PlanRANIERI RICHARD J · Director · $67.4KJun 17, 2026Filing
  • Insider sellInsider Sell $67K · 10b5-1 PlanGUSTAFSON KURT A · Director · $67.4KJun 17, 2026Filing
  • Insider sellInsider Sell $93K · 10b5-1 PlanGORMAN KEVIN CHARLES · Director · $92.7KJun 17, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing
  • 8-K eventPhase 1 Study ResultsMay 5, 2026Filing
  • 8-K eventExecutive Severance PolicyApr 27, 2026Filing

Questions

Frequently asked questions

What is Xencor, Inc.'s market cap?

Xencor, Inc. (XNCR) has a market capitalization of $885.3M.

What is XNCR's P/E ratio?

A meaningful P/E ratio is not available for XNCR — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is XNCR's price-to-book (P/B) ratio?

XNCR trades at 1.39 times book value per share.

Are insiders buying XNCR stock?

SEC Form 4 filings show no open-market insider buys at Xencor, Inc. in the last 90 days (6 sells).

Same arena

Related companies in Biotechnology

JANX

Janux Therapeutics, Inc.

$894.3M

KURA

Kura Oncology, Inc.

$900.2M

SPRY

ARS Pharmaceuticals, Inc.

$908.6M

ABUS

Arbutus Biopharma Corporation

$922.5M

TBPH

Theravance Biopharma, Inc.

$835.7M

ETON

Eton Pharmaceuticals, Inc.

$834.6M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.